Company profile for Autifony Therapeutics

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Autifony Therapeutics Limited is a UK-based company formed in 2011 as a spin-out from GlaxoSmithKline by Charles Large and Giuseppe Alvaro, previously Directors in GSK’s Neuroscience Centre of Excellence for Drug Discovery. Autifony is using its pioneering approach to develop novel treatments for serious disorders of the central nervous system, such as Schizophrenia, Fragile X, Alzheimer’s Disease and potentially other di...
Autifony Therapeutics Limited is a UK-based company formed in 2011 as a spin-out from GlaxoSmithKline by Charles Large and Giuseppe Alvaro, previously Directors in GSK’s Neuroscience Centre of Excellence for Drug Discovery. Autifony is using its pioneering approach to develop novel treatments for serious disorders of the central nervous system, such as Schizophrenia, Fragile X, Alzheimer’s Disease and potentially other diseases which represent major unmet medical needs. The company is also one of the leaders in pharmaceutical approaches to the treatment of hearing disorders.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
United Kingdom
Address
Address
Stevenage Bioscience Catalyst, Gunnels Wood Road, Stevenage, Hertfordshire, SG...
Telephone
Telephone
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

DDL Conference

Not Confirmed

envelop Contact Supplier

DDL Conference

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more
 Jazz puts up $771M to form Autifony neuroscience discovery pact
Jazz puts up $771M to form Autifony neuroscience discovery pact

15 Nov 2023

// Nick Paul Taylor FIERCE BIOTECH

https://www.fiercebiotech.com/biotech/jazz-locks-arms-gsk-spinout-autifony-putting-771m-form-neuroscience-discovery-pact

Nick Paul Taylor FIERCE BIOTECH
15 Nov 2023

https://www.businesswire.com/news/home/20230613182220/en

BUSINESSWIRE
13 Jun 2023

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty